| Clinicopathological features |
|
|
| Total number of cases |
200 |
% |
| Gender |
Males |
128 |
64% |
| |
Female |
72 |
36% |
| Stage |
CP-CML |
81 |
40.50% |
| |
AP-CML |
54 |
27% |
| |
BC-CML |
65 |
32.50% |
| BCR-ABL type |
a2b2 |
59 |
29.50% |
| |
a2b3 |
124 |
62% |
| |
a2b2/ a2b3 |
17 |
8.50% |
| Therapy |
Imatinib |
200 |
|
| Age group |
Age >45 |
71 |
35.50% |
| |
Age <45 |
129 |
64.50% |
| Molecular response |
MMR |
50 |
25% |
| |
No MR |
150 |
75% |
| Haematological response |
MHR |
30 |
15% |
| |
Minor HR |
46 |
23% |
| |
Loss HR |
124 |
62% |
| Thrombocytopenia |
|
100 |
50% |
|